Drugs / MBF-118
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05921916 | Jul 2020 → Sep 2022 | cancer | Medibiofarma S.L. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05940558 | Apr 2023 → Sep 2024 | Crohn disease | Medibiofarma S.L. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-09 | Medibiofarma S.L. | Results Medibiofarma Successfully Completes Phase 2A Clinical Trial of MBF-118 for Fibrotic Crohn’s Disease medibiofarma.com ↗
The recently completed Phase 2A trial marks a significant milestone, as it is the first trial to demonstrate the excellent safety and tolerability of MBF-118 in patients with Crohn’s Disease. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBF-118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05940558 ↗ |
| Action | Activate | “PPAR gamma receptor partial agonist” NCT05921916 ↗ |
| Route | Oral | “MBF-118 will be administered as single oral ascending dose” NCT05921916 ↗ |